Targeting neoantigens conserved across organs and species overcomes tumor immune escape Neoantigen-targeted immunotherapies hold promise for cancer treatment, but current personalized approaches are time-consuming and costly. Here, we identify neoantigens encoded by Ptprs and Igf2r that ...

We're excited to share our latest work: "Targeting neoantigens conserved across organs and species overcomes tumor immune escape"!

Thanks to the team at @sinaiimmuno.bsky.social !
www.biorxiv.org/content/10.1...

@francoisrousset.bsky.social will give a talk at Mount Sinai Hospital on May 7th. If interested, please do not hesitate to reach out!

@sinaiimmuno.bsky.social

Glad to share our work about resistance to immunotherapy! We discovered a combination therapy allowing to eliminate 100% of MMRd CRC tumors and >70% or MMRp CRC tumors. We also identified the T cell and macrophage subsets mediating the response. Thanks to the team! www.biorxiv.org/content/10.1...